Abstract
Background Recent studies suggested short-term mortality after transcatheter edge-to-edge repair (TEER) was comparable between male and female. However, the sex-specific prognostic difference in long-term follow-up after TEER is still unknown. To evaluate the impact of sex on long-term mortality after TEER for functional mitral regurgitation (FMR) using multicenter registry data.
Methods We retrospectively analyzed 1220 patients (male 60.3%) who underwent TEER for FMR at 24 centers. Impact of sex on all-cause death and hospitalization for heart failure (HF) after TEER was evaluated using multivariate regression analysis and propensity score (PS) matching methods.
Results During the two-year follow-up, 205 all-cause death and 259 hospitalizations for HF were observed after TEER for FMR. Male had a significantly lower incidence of all-cause death than female (18.7% vs. 14.0%, log-rank p < 0.01). After adjustment by multivariate Cox-regression and PS matching, male was significantly associated with a higher incidence of all-cause mortality after TEER than female (hazard ratio [HR] 2.24, 95% confidence interval [CI] 1.48 to 3.39 in multivariate Cox-regression; HR 2.04, 95% CI 1.17 to 3.57 in PS matching). The sex-specific prognostic difference was even more pronounced after 1-year of TEER. On contrary, there was no sex-related difference in hospitalization for HF after TEER.
Conclusions Male had a higher incidence of two-year all-cause death during after TEER for FMR than female, while this was not observed in hospitalization for HF. This result might indicate that female with FMR is more likely to benefit from TEER for better prognosis.
What is known?There were conflicting results in sex-related prognostic difference after TEER for FMR.
What the study adds During two-year follow-up period, male had higher increased risk of mortality after TEER than female in multivariate regression and propensity score matched analysis, while there was no sex-related difference in hospitalization for HF after TEER. Female with FMR might be likely to derived benefit from TEER concomitant with GDMT as compared to male.
Competing Interest Statement
Hioki and Dr. Asami received honoraria for lecture from Abbott Medical. Drs. Yamamoto, Watanabe, Kataoka, Kubo, Izumo, Mizuno, Nakajima, and Shirai are clinical proctors of transcatheter edge-to-edge repair for Abbott Medical. Dr. Saji is a clinical proctor of transcatheter edge-to-edge repair for Abbott Medical and received consultant fee from Abbott Medical. Dr. Ohno is advisor of Abbott Medical and received consultant and speaker fee from Abbott Medical. Dr. Yamaguchi is a clinical proctor of transcatheter edge-to-edge repair for Abbott Medical and received a lecture fee and a scholarship donation from Abbott Medical. The remaining authors have nothing to disclose.
Clinical Trial
UMIN000023653
Funding Statement
The OCEAN-Mitral registry is supported by the Edwards-Lifesciences, Medtronic, Abbott Medical, Boston Scientific, and Daiichi-Sankyo company. The sponsor was not involved in the study conduct, data collection, statistical analysis, and writing of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was developed in accordance with the Declaration of Helsinki and was approved by the ethics committee of each participating hospital.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author.
Abbreviations List
- FMR
- functional mitral regurgitation
- HF
- heart failure
- TEER
- transcatheter edge-to-edge repair